42 related articles for article (PubMed ID: 38493076)
1. Characterization of metabolic alterations of chronic lymphocytic leukemia in the lymph node microenvironment.
Chen Z; Simon-Molas H; Cretenet G; Valle-Argos B; Smith LD; Forconi F; Schomakers BV; van Weeghel M; Bryant DJ; van Bruggen JAC; Peters FS; Rathmell JC; van der Windt GJW; Kater AP; Packham G; Eldering E
Blood; 2022 Aug; 140(6):630-643. PubMed ID: 35486832
[TBL] [Abstract][Full Text] [Related]
2. Chronic lymphocytic leukemia cells in a lymph node microenvironment depict molecular signature associated with an aggressive disease.
Mittal AK; Chaturvedi NK; Rai KJ; Gilling-Cutucache CE; Nordgren TM; Moragues M; Lu R; Opavsky R; Bociek GR; Weisenburger DD; Iqbal J; Joshi SS
Mol Med; 2014 Jul; 20(1):290-301. PubMed ID: 24800836
[TBL] [Abstract][Full Text] [Related]
3. Lymph node-induced immune tolerance in chronic lymphocytic leukaemia: a role for caveolin-1.
Gilling CE; Mittal AK; Chaturvedi NK; Iqbal J; Aoun P; Bierman PJ; Bociek RG; Weisenburger DD; Joshi SS
Br J Haematol; 2012 Jul; 158(2):216-231. PubMed ID: 22571278
[TBL] [Abstract][Full Text] [Related]
4. Metabolic reprogramming in the CLL TME; potential for new therapeutic targets.
Simon-Molas H; Montironi C; Kabanova A; Eldering E
Semin Hematol; 2024 Feb; ():. PubMed ID: 38493076
[TBL] [Abstract][Full Text] [Related]
5. Targeting metabolic reprogramming in chronic lymphocytic leukemia.
Nie Y; Yun X; Zhang Y; Wang X
Exp Hematol Oncol; 2022 Jun; 11(1):39. PubMed ID: 35761419
[TBL] [Abstract][Full Text] [Related]
6. Targeting the tumor microenvironment in chronic lymphocytic leukemia.
Svanberg R; Janum S; Patten PEM; Ramsay AG; Niemann CU
Haematologica; 2021 Sep; 106(9):2312-2324. PubMed ID: 33882636
[TBL] [Abstract][Full Text] [Related]
7. Metabolism pathways in chronic lymphocytic leukemia.
Rozovski U; Hazan-Halevy I; Barzilai M; Keating MJ; Estrov Z
Leuk Lymphoma; 2016; 57(4):758-65. PubMed ID: 26643954
[TBL] [Abstract][Full Text] [Related]
8. Metabolic rewiring beyond Warburg in chronic lymphocytic leukemia: How much do we actually know?
Galicia-Vázquez G; Aloyz R
Crit Rev Oncol Hematol; 2019 Feb; 134():65-70. PubMed ID: 30771875
[TBL] [Abstract][Full Text] [Related]
9. Chronic Lymphocytic Leukemia: Disease Biology.
Koehrer S; Burger JA
Acta Haematol; 2024; 147(1):8-21. PubMed ID: 37717577
[TBL] [Abstract][Full Text] [Related]
10. Survival and Immunosuppression Induced by Hepatocyte Growth Factor in Chronic Lymphocytic Leukemia.
Giannoni P; Cutrona G; Totero D
Curr Mol Med; 2017; 17(1):24-33. PubMed ID: 28231754
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
